Analysts raise TearLab price targets

Tweet Analysts at Canaccord Genuity, Felt & Co., Roth Capital Markets and Craig-Hallum Capital Group raised their price targets on “buy and strong buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) after the company’s first quarter results and systems orders beat consensus estimates. The stock was changing hands at $9.03, up 13%, after touching a 52-week high of $9.16 [...]

Novadaq selling $50.3-million of common shares

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) is selling $50.3-million of common shares at a price of $12.90 apiece through an underwriting agreement with Canaccord Genuity. The offering is being conducted in the U.S. under the company’s shelf registration statement filed with the SEC and in Canada under a final short-form base shelf prospectus filed with the [...]

Analysts: Early Novadaq PILLAR II data delivers

Tweet In a new research report, analyst Jason Mills of Canaccord Genuity discussed initial data presented at the SAGES conference Thursday evening by Dr. Michael Stamos of the University of California at Irvine from the PILLAR II study, which is evaluating the ability of Novadaq Technologies’ (NASDAQ:NVDQ; TSX:NDQ) PINPOINT endoscopic fluorescence imaging system to assess [...]

Isotechnika updates investors on planned merger with Aurinia

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have updated investors on their proposed merger to create a global nephrology company. The companies have now executed a definitive tripartite agreement with ILJIN Life Science. Subject to the successful completion of the proposed merger, the combined company will re-acquire full rights to voclosporin for autoimmune indications, [...]

David Dodd named CEO of Aeterna Zentaris

Tweet Aeterna Zentaris (NASDAQ:AEZS; TSX:AEZ) has appointed David Dodd as president and CEO, and a director, succeeding Juergen Engel. “With the appointment of David, we are taking an important first step in transforming Aeterna Zentaris from a company focused on R&D to a company focused on commercializing the promising compounds in our pipeline,” chairman Juergen [...]

Canaccord lifts Spectranetics price target to $18.50

Tweet Canaccord Genuity has raised its price target on “buy-rated” Spectranetics (NASDAQ:SPNC) to $18.50 from $17.50, citing its forecast of solid fourth quarter results. “What’s more, our recent meeting with management highlighted a stable of new products/market opportunities that we believe could augment Spectranetics’ growth and profitability going forward – namely in-stent restenosis (FDA approval [...]

Canaccord ups TearLab price target to $8

Tweet Canaccord Genuity has raised its price target on “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $8 from $6, saying the growth profile of the stock justifies a higher multiple than its peer group. The stock closed at $5.31 on Friday. “In our opinion, TearLab should start benefitting from physician referrals (>500 IB), expanding sales force (12 [...]

In conversation with Jeffrey Frelick

Tweet Jeffrey Frelick’s road to Wall Street began as a laboratory technologist with Clinical Pathology Facility before he joined Becton Dickinson in 1991 as a sales representative and regional sales manager. He also has been a consultant with Boston Biomedical Consultants, where he provided strategic planning assistance and market research data and conducted due diligence [...]

Canaccord confident in Novadaq technology & IP

Tweet Responding to a recent stock slide by Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ), Canaccord Genuity says that based on its due diligence, “we strongly believe the company possesses robust, clinically relevant, proprietary technology that is secured by strong IP.” Analyst Jason Mills reiterated his “buy” rating and $15 price target and recommends investors “buy the weakness [...]

Canaccord ups Allon price target

Tweet Canaccord Genuity has raised its price target on “speculative buy-rated” Allon Therapeutics (TSX:NPC) to $1 from 65 cents, following third quarter results. The stock closed at 42 cents on Tuesday. Allon posted a third quarter loss of $1.9-million, lower than Canaccord’s estimate of $3-million. The variance was driven by lower R&D expenditures of $1.3-million [...]

Next Page »